Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Exclusion Criteria

• •Patients with a mean of \>20% of the intratrabecular marrow space involved with lymphoma on bone marrow biopsy following induction Rituximab therapy.
• •Transformed follicular lymphoma and discordant lymphoma
• •Patients with active obstructive hydronephrosis.
• •Patients with initial disease bulk greater than 10cm.
• •Patients with evidence of active infection requiring i.v. antibiotics at the time of study entry.
• •Patients with congestive heart failure stage III or IV of NYHA classification, myocardial infraction or unstable angina within 6 months or other serious illness that would preclude evaluation.
• •Patients with left VEF \< 40%
• •Patients with large pleural or peritoneal effusions.
• •Patients with known HIV infection or active HBV (HbsAg positivity) or HCV infection.
• •Known Hypersensitivity to murine antibodies or proteins
• •Patients who are pregnant or breast-feeding. Male and female patients must agree to use effective contraception for 12 months following 90Y-ibritumomab tiuxetan antibody therapy.
• •Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years.